<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Atrophic rhinosinusitis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Atrophic rhinosinusitis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Atrophic rhinosinusitis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard D deShazo, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Scott Stringer, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonathan Corren, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anna M Feldweg, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 28, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Atrophic rhinitis is an uncommon and distinct clinical syndrome of progressive atrophy of the nasal mucosa. It is characterized by paradoxical nasal congestion and thick, troublesome nasal secretions and complicated by bacterial colonization and infection. Enlargement of the nasal cavities may occur in some forms. Most patients also have concomitant sinusitis, and thus, the disorder is more accurately called atrophic rhinosinusitis. There are primary and secondary forms of this disorder, which affect different populations and have distinct presentations.</p><p>This topic will discuss the classification, clinical manifestations, diagnosis, and management of atrophic rhinosinusitis. Other forms of chronic rhinosinusitis are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/7528.html" rel="external">"Chronic rhinosinusitis: Clinical manifestations, pathophysiology, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/121195.html" rel="external">"Chronic rhinosinusitis with nasal polyposis: Management and prognosis"</a> and  <a class="medical medical_review" href="/z/d/html/121194.html" rel="external">"Chronic rhinosinusitis without nasal polyposis: Management and prognosis"</a>.)</p><p class="headingAnchor" id="H18731467"><span class="h1">CLASSIFICATION</span><span class="headingEndMark"> — </span>Atrophic rhinosinusitis may be categorized into two forms: primary (or idiopathic) and secondary.</p><p class="bulletIndent1"><span class="glyph">●</span>The primary form is seen primarily in young people in the developing world. It is associated with mucosal colonization, predominantly with <em>Klebsiella ozaenae</em>, as well as other organisms. The primary presenting symptom is foul-smelling nasal discharge.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Secondary atrophic rhinosinusitis is seen with some regularity in the developed world and occurs in patients who underwent prior sinonasal trauma, surgery, radiation therapy, or have certain inflammatory conditions (granulomatous diseases).</p><p></p><p class="headingAnchor" id="H2"><span class="h1">PRIMARY ATROPHIC RHINOSINUSITIS</span><span class="headingEndMark"> — </span>Primary (idiopathic) atrophic rhinosinusitis is principally reported among patients from lower socioeconomic groups living in geographic areas with warm climates [<a href="#rid1">1-3</a>]. Areas of high prevalence include southern Saudi Arabia, China, Africa, India, the Mediterranean, and the Philippines. It is uncommon in the United States and Europe, although it should be considered in immigrants from these areas [<a href="#rid4">4</a>]. The low incidence in developed countries has been suggested to be at least in part due to widespread availability of antibiotics [<a href="#rid5">5</a>]. By definition, there is no history of nasal trauma or surgery, granulomatous disease, or sinonasal radiation prior to the onset of symptoms.</p><p>Women are affected more often than men, and younger people are affected more often than older adults. [<a href="#rid3">3,5,6</a>]. In one study of 100 cases from China, 86 patients were less than 30 years of age [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H3"><span class="h2">Symptoms</span><span class="headingEndMark"> — </span>Patients with primary atrophic rhinosinusitis present with halitosis, which is noticeable to others. The patients themselves can also perceive a constant bad odor (cacosmia). This is the origin of the term "ozena" ("the stench"), which is sometimes used as a synonym for severe primary atrophic rhinosinusitis [<a href="#rid3">3</a>]. However, this unfortunate descriptor both stigmatizes and embarrasses affected patients and should be avoided. Other symptoms include anosmia, epistaxis, nasal pain, sleep disruption, and choking from aspiration of crusts [<a href="#rid5">5,7,8</a>].</p><p>In a Thai series of 47 patients with primary atrophic rhinosinusitis, the most common presenting symptoms were nasal crusts (54 percent), purulent discharge (43 percent), foul smell (41 percent), and nasal obstruction (37 percent) [<a href="#rid3">3</a>].</p><p>Patients may report congestion, even those with abnormally enlarged nasal cavities, because the sensation of obstruction can arise from abnormal airflow through the nose or a lack of sensation of airflow due to the loss of tissue containing sensory receptors. The same phenomenon may be seen in patients with nasal septal perforation.</p><p class="headingAnchor" id="H4"><span class="h2">Nasal exam</span><span class="headingEndMark"> — </span>Nasal exam reveals a shiny, thin, pale, and sometimes ulcerated mucosa covered by thick yellow, brown, or green crusts, which may be bloody or covered with purulence. Resorption of underlying bone leads to enlargement of the nasal cavities and bowing of the lateral nasal wall in some cases. Nasal septal perforation and secondary saddle nose deformity may also occur [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H3730026"><span class="h2">Pathophysiology</span><span class="headingEndMark"> — </span>The factors that predispose certain individuals to develop primary atrophic rhinosinusitis are not definitively known, although various developmental, endocrine, vascular, nutritional, anatomic, infectious, and autoimmune factors have been postulated to be relevant. In the Thai study, many patients either came from rural areas or worked in factories, suggesting that specific environmental exposures may play a role [<a href="#rid3">3</a>]. A genetic association was suggested in other reports [<a href="#rid10">10</a>].</p><p>Histologically, the disease is characterized by replacement of the normal pseudostratified columnar epithelium with a metaplastic, predominantly squamous epithelium [<a href="#rid8">8,11</a>]. This abnormal tissue is devoid of cilia and mucus-producing goblet cells. Additional findings may include an inflammatory cell infiltrate composed of lymphocytes and plasma cells and vascular abnormalities ranging from neovascularity to arteritis obliterans  (<a class="graphic graphic_table graphicRef50119" href="/z/d/graphic/50119.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H5"><span class="h2">Microbiology</span><span class="headingEndMark"> — </span>Colonization and frank infection of the nose and sinuses occurs with <em>K. ozaenae</em> and other organisms, including <em>Proteus</em> species, <em>Escherichia coli</em>, <em>Staphylococcus aureus</em>, <em>Streptococcus pneumoniae</em>, and others [<a href="#rid3">3,12</a>].</p><p class="headingAnchor" id="H6"><span class="h2">Radiographic findings</span><span class="headingEndMark"> — </span>Computed tomography (CT) may reveal some combination of the following features  (<a class="graphic graphic_diagnosticimage graphicRef64095" href="/z/d/graphic/64095.html" rel="external">image 1</a>) [<a href="#rid3">3,13</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Mucosal atrophy of the inferior and middle turbinates and bony resorption</p><p class="bulletIndent1"><span class="glyph">●</span>Resorption of the ethmoid bulla and uncinate process with loss of definition of the ostiomeatal complex</p><p class="bulletIndent1"><span class="glyph">●</span>Enlargement of the nasal cavities with destruction of the lateral nasal wall</p><p class="bulletIndent1"><span class="glyph">●</span>Mucosal thickening in the paranasal sinuses</p><p class="bulletIndent1"><span class="glyph">●</span>Hypoplasia of the maxillary sinuses with decreased pneumatization</p><p></p><p class="headingAnchor" id="H8"><span class="h1">SECONDARY ATROPHIC RHINOSINUSITIS</span><span class="headingEndMark"> — </span>Data on patients with secondary atrophic rhinosinusitis are sparse, although such patients are not unusual in referral practices in allergy and immunology and otolaryngology. A common feature is longstanding trauma or inflammation of the nasal cavity surface, culminating in mucosal damage, nasal crusting, and superinfection. Patients with atrophic rhinosinusitis differ from those with standard chronic rhinosinusitis in the intractable nature of their symptoms and ongoing mucopurulence.</p><p>We distinguish two subtypes of secondary atrophic rhinosinusitis: a "wet" form and a "dry" form.</p><p class="bulletIndent1"><span class="glyph">●</span>The typical patient with the wet form is one who has had multiple sinonasal surgeries and now experiences chronic rhinosinusitis with production of purulent mucous. When cultured, the nasal discharge grows coliforms, often <em>E. coli</em>. Most patients we see have been treated with multiple antibiotics, to the point that these organisms are resistant to all antibiotics. These patients have stagnant mucus that is superinfected, rather than a traditional sinusitis. Antibiotics do not resolve this condition and often make it worse.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with the dry form of secondary atrophic rhinosinusitis have dry noses with bloody scabs. We see this most commonly with sarcoidosis of the upper respiratory tract.</p><p></p><p class="headingAnchor" id="H9"><span class="h2">Associated conditions</span><span class="headingEndMark"> — </span>Secondary atrophic rhinosinusitis is seen in association with [<a href="#rid5">5</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Repeated sinonasal surgeries – Extensive and repeated surgery can both cause and exacerbate atrophic rhinosinusitis. Affected patients may have undergone multiple sinus surgeries (often with radical middle and/or inferior turbinectomy) for chronic rhinosinusitis, allergic fungal rhinosinusitis, and/or nasal sarcoidosis [<a href="#rid14">14</a>]. This form of partially iatrogenic secondary atrophic rhinosinusitis is sometimes called "empty nose syndrome" [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sinonasal trauma, especially trauma requiring extensive surgical corrections.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sinonasal radiation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Granulomatous diseases of the upper respiratory tract, such as leprosy, tuberculosis, sarcoidosis, granulomatosis with polyangiitis, or syphilis.</p><p></p><p class="headingAnchor" id="H10"><span class="h2">Symptoms and signs</span><span class="headingEndMark"> — </span>In a review of 242 patients of whom 197 had secondary atrophic rhinosinusitis, all reported congestion, daily nasal crusting, and dryness [<a href="#rid5">5</a>]. About one-half of patients experienced social isolation and depression. Other common symptoms were:</p><p class="bulletIndent1"><span class="glyph">●</span>Facial pain</p><p class="bulletIndent1"><span class="glyph">●</span>Recurrent epistaxis</p><p class="bulletIndent1"><span class="glyph">●</span>Episodic anosmia</p><p></p><p>Patients with secondary atrophic rhinosinusitis may also report persistent postnasal drip, cacosmia, and episodes of frank sinusitis. Some present as "nasal cripples," or people whose lives are disrupted by persistent nasal symptoms.</p><p>Some patients have thick, viscous, mucopurulent secretions, and these individuals may have underlying inflammatory diseases. In contrast, others report intractable nasal dryness and may use tweezers to remove dry, bloody crusts from the nasal passages [<a href="#rid16">16</a>]. This "dry" presentation may represent a later stage of the disease that results from destruction and loss of the mucus-secreting glandular epithelium.</p><p class="headingAnchor" id="H11"><span class="h2">Nasal exam findings</span><span class="headingEndMark"> — </span>Rhinoscopy usually reveals a thin edematous or granular erythematous mucosa with lesser degrees of nasal bleeding, crusting, and purulence. Widening of the nasal airway due to resorption of underlying cartilage is less common with the secondary forms of the disease, compared with primary disease.</p><p class="headingAnchor" id="H12"><span class="h2">Microbiology</span><span class="headingEndMark"> — </span>In the authors' experience, superinfection on nasal culture is more common with <em>Pseudomonas aeruginosa</em> and <em>S. aureus</em> than with other organisms. It is frequently difficult to assess if symptoms are related to bacterial infection or if the bacteria represent colonization of a damaged epithelium with poor mucociliary function.</p><p class="headingAnchor" id="H13"><span class="h2">Radiography</span><span class="headingEndMark"> — </span>There is no single set of radiologic findings pathognomonic for secondary atrophic rhinosinusitis. Radiographic findings reflect secondary infection complicating the atrophic rhinosinusitis, rather than the atrophic changes directly [<a href="#rid16">16</a>]. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>Postsurgical or long-standing atrophic rhinosinusitis may appear on computed tomography (CT) as an absence or reduction in the size of the middle or inferior turbinates, nearly complete absence of the septae of the ethmoid sinuses, and/or mucosal thickening throughout the paranasal sinuses.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Granulomatous and postradiation-induced atrophic rhinosinusitis may present radiologically with diffuse mucosal changes throughout the paranasal sinuses and a marked prominence of the soft tissues of the turbinates.</p><p></p><p class="headingAnchor" id="H14"><span class="h2">Pathology</span><span class="headingEndMark"> — </span>Pathologic findings in secondary atrophic rhinosinusitis are similar to those of primary disease. However, vascular changes and resorption of bone are not observed  (<a class="graphic graphic_table graphicRef50119" href="/z/d/graphic/50119.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H2375605219"><span class="h1">EVALUATION AND DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis (either primary or secondary) is based upon the presence of appropriate symptoms and physical findings, combined with consistent findings on computed tomography (CT) of the sinuses.</p><p class="headingAnchor" id="H560366"><span class="h2">Diagnostic criteria</span><span class="headingEndMark"> — </span>Diagnostic criteria for <strong>secondary</strong> atrophic rhinosinusitis have been proposed, which incorporate elements of the history and physical examination. These criteria were based on an analysis of 22 patients in whom there was consensus between the treating otolaryngologist and allergist/immunologist that the best diagnosis was atrophic rhinosinusitis, compared with 22 patients with various other types of chronic rhinosinusitis [<a href="#rid16">16</a>].</p><p>Six criteria were identified that were characteristic and specific to patients with secondary atrophic rhinosinusitis.</p><p class="bulletIndent1"><span class="glyph">●</span>Patient-reported:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Recurrent epistaxis</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Episodic anosmia</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clinician-documented:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Nasal purulence</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Nasal crusting</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Chronic inflammatory disease involving the upper airway (eg, sarcoidosis, granulomatosis with polyangiitis, etc)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Two or more sinonasal surgeries</p><p></p><p>Patients with <strong>two or more criteria</strong> could be assigned the diagnosis of atrophic rhinosinusitis, with a sensitivity of 0.95 and a specificity of 0.77 [<a href="#rid16">16,17</a>]. Of note, chronic nasal obstruction was common but not specific to patients with atrophic rhinosinusitis, so this was excluded as a criterion. The six criteria listed above occurred more often in patients with atrophic rhinosinusitis compared with other forms of rhinosinusitis.</p><p>In addition to the standard history and physical examination, we perform rhinoscopy with a nasal endoscope after spraying the nose with a topical anesthetic/decongestant. Although the findings may be detectable with a simple nasal speculum exam in some cases, nasal endoscopy allows for a more complete appreciation of the extent of disease and is essential in subsequent management. Nasal endoscopy is usually performed by an otolaryngologist or by an allergist with specific training in this procedure.</p><p>Nasal cultures positive for coliforms are supportive of the diagnosis, although these are not routinely performed or used to guide therapy.</p><p class="headingAnchor" id="H560424"><span class="h2">Imaging</span><span class="headingEndMark"> — </span>CT is the recommended imaging methodology for evaluation of patients with symptoms consistent with atrophic rhinosinusitis (if not already performed). Routine sinus radiographs are no longer used in the evaluation of rhinosinusitis in developed countries.</p><p class="headingAnchor" id="H17"><span class="h2">Evaluation for underlying systemic disease</span><span class="headingEndMark"> — </span>An undetected inflammatory disorder, such as leprosy, sarcoidosis, granulomatosis with polyangiitis, or syphilis, should be considered if systemic symptoms, such as weight loss or shortness of breath, are present or if there is chronic epistaxis. In this setting, laboratory evidence of a systemic disorder (such as hematologic and/or renal abnormalities) or an abnormal chest radiograph may also suggest an underlying inflammatory process.</p><p class="headingAnchor" id="H18"><span class="h3">Nasal biopsy</span><span class="headingEndMark"> — </span>A nasal biopsy should be obtained if there is a question of secondary atrophic rhinosinusitis due to an underlying inflammatory process. Depending on the patient's history, examination for fungus, acid fast mycobacteria, spirochetes, or granulomatous changes may be helpful. (See  <a class="medical medical_review" href="/z/d/html/2452.html" rel="external">"Fungal rhinosinusitis"</a> and  <a class="medical medical_review" href="/z/d/html/7588.html" rel="external">"Syphilis: Screening and diagnostic testing"</a> and  <a class="medical medical_review" href="/z/d/html/3117.html" rel="external">"Granulomatosis with polyangiitis and microscopic polyangiitis: Clinical manifestations and diagnosis"</a>.)</p><p class="headingAnchor" id="H19"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>"Rhinitis sicca anterior" and dry nose syndromes are poorly defined disorders that probably sit on the continuum from mild-to-severe secondary atrophic rhinosinusitis.</p><p>Additional discussions related to the differential diagnosis of patients with symptoms and signs suggestive of rhinosinusitis are presented separately. (See  <a class="medical medical_review" href="/z/d/html/7532.html" rel="external">"Chronic nonallergic rhinitis"</a> and  <a class="medical medical_review" href="/z/d/html/7533.html" rel="external">"An overview of rhinitis"</a>.)</p><p class="headingAnchor" id="H21"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>Controlled trials evaluating therapies for atrophic rhinosinusitis are lacking [<a href="#rid18">18</a>], and the literature supporting various therapies is limited to observational studies and case reports. Our approach to management of atrophic rhinosinusitis is empiric and is described in detail in the following section. Daily therapy includes nasal lavage and lubrication. Topical antibiotics are added when indicated. Any underlying active disease process, such as sarcoidosis or granulomatosis with polyangiitis, must be treated if present. (See  <a class="medical medical_review" href="/z/d/html/3105.html" rel="external">"Granulomatosis with polyangiitis and microscopic polyangiitis: Induction and maintenance therapy"</a>.)</p><p class="headingAnchor" id="H22"><span class="h2">Nasal lavage and lubrication</span><span class="headingEndMark"> — </span>Nasal lavage is recommended to prevent formation of crusts and drying of the atrophic nasal lining. It is associated with improvement in a variety of rhinitis conditions and carries little risk if properly performed, although it has not been specifically studied in the treatment of atrophic rhinosinusitis [<a href="#rid19">19</a>].</p><p>Patients with atrophic rhinosinusitis are encouraged to lavage their noses with warmed isotonic <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> at least twice daily  (<a class="graphic graphic_table graphicRef78832" href="/z/d/graphic/78832.html" rel="external">table 2</a>). We recommend using an oral irrigating device (eg, Waterpik or similar product) with a tip for nasal irrigation (eg, Grossan tip or similar product). Other devices, such as bulb syringes, bottle sprayers, and nebulizers are also effective, provided the system delivers an adequate volume of solution (&gt;200 mL per side) into the nose [<a href="#rid19">19</a>].</p><p>After lavage, we use one of several agents to lubricate the mucosa. Acceptable products include petroleum jelly or personal lubricants. Xylitol-containing <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> sprays may be useful when applied regularly to the nasal cavity.</p><p class="headingAnchor" id="H23"><span class="h2">Antibiotics</span><span class="headingEndMark"> — </span>Few data exist concerning the efficacy of antibiotics added to lavage solutions in atrophic rhinosinusitis. However, case reports and small series of patients with recalcitrant rhinitis from various etiologies have found the intervention helpful [<a href="#rid20">20</a>]. Theoretically, lavage with antibiotic solutions provides relatively high concentrations of drug directly to the nasal cavity, which is the site of the pathology in atrophic rhinosinusitis, in contrast to chronic rhinosinusitis, in which the pathology involves the sinuses more than the nasal passages.</p><p>It has been our experience that this intervention is helpful. An antibiotic may be added to the lavage when the nasal wash or nasal discharge becomes persistently purulent for more than two days  (<a class="graphic graphic_table graphicRef55661" href="/z/d/graphic/55661.html" rel="external">table 3</a>) [<a href="#rid20">20</a>]. We use <a class="drug drug_general" data-topicid="9668" href="/z/d/drug information/9668.html" rel="external">mupirocin</a> initially. Quinolone or aminoglycoside rinses are used when gram-negative organisms are suspected. The antibiotic solution is used twice daily until the patient no longer notes purulent nasal discharge and/or purulence clears from the lavage solution.</p><p>The oral administration of antibiotics may also be required for acute infections [<a href="#rid21">21</a>]. We generally use broad-spectrum antibiotics for patients with secondary disease, although there are no specific studies examining choice of antibiotics in this situation. <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">Rifampin</a> has been studied in a small number of patients with the primary form of the disease [<a href="#rid22">22</a>]. (See  <a class="medical medical_review" href="/z/d/html/83012.html" rel="external">"Uncomplicated acute sinusitis and rhinosinusitis in adults: Treatment"</a>.)</p><p class="headingAnchor" id="H20790803"><span class="h2">Other therapies</span><span class="headingEndMark"> — </span>For patients with secondary atrophic rhinosinusitis and active nasal inflammation, we use intranasal glucocorticoids either in nasal sprays or lavage. We have not observed any complications, and often, there is some symptomatic improvement in our experience. However, other experts suggest avoiding intranasal glucocorticoids, and data are lacking.</p><p>A number of surgical procedures have been proposed. However, controlled trials have not been performed to adequately assess their efficacy. Temporary closure of the nostrils to facilitate regrowth of the nasal epithelium (Young's operation) is primarily of historic interest and rarely performed. Surgical submucosal implantation of a variety of biosynthetic materials or autologous cartilage to decrease the nasal volume may improve clinical symptoms in some but not all patients with empty nose syndrome [<a href="#rid1">1,22,23</a>]. Since adequate scientific scrutiny has not been performed, these procedures are not routinely performed.</p><p class="headingAnchor" id="H10110674"><span class="h2">Therapies that are not recommended</span><span class="headingEndMark"> — </span>Decongestants, both oral and topical, may be harmful to the already compromised vascular supply to the nasal mucosal tissues. We advise patients to avoid these.</p><p class="headingAnchor" id="H20790815"><span class="h2">Monitoring</span><span class="headingEndMark"> — </span>We perform surveillance nasal endoscopy at least twice per year as long as symptoms persist to remove adhesions (synechiae) and excessive crusting. This should be performed by an otolaryngologist or other clinician trained in nasal endoscopy, as excessive bleeding may result if the procedure is improperly done.</p><p class="headingAnchor" id="H3730256"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>In many cases, atrophic rhinosinusitis is a lifelong condition. However, in our experience, the secondary form of the disease seems to "burn out" spontaneously in a subset of patients. That is, the wet form sometimes transforms into the dry form. (See <a class="local">'Secondary atrophic rhinosinusitis'</a> above.)</p><p class="headingAnchor" id="H1376811139"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110441.html" rel="external">"Society guideline links: Chronic rhinosinusitis"</a>.)</p><p class="headingAnchor" id="H26"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>The Basics topic (see  <a class="medical medical_basics" href="/z/d/html/86630.html" rel="external">"Patient education: How to rinse out your nose with salt water (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H27"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Atrophic rhinosinusitis is a syndrome of progressive atrophy and bacterial colonization of the nasal mucosa. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Primary (idiopathic) atrophic rhinosinusitis is the more severe form of the condition and is predominantly seen in developing countries. (See <a class="local">'Primary atrophic rhinosinusitis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The secondary form, which is associated with nasal surgery, trauma, radiation, and granulomatous diseases is more common in developed countries. (See <a class="local">'Secondary atrophic rhinosinusitis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Symptoms include chronic nasal congestion, crusting of nasal secretions, halitosis, anosmia, epistaxis, sleep disruption, and depression. (See <a class="local">'Symptoms'</a> above and <a class="local">'Symptoms and signs'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nasal endoscopy reveals a thin, erythematous mucosa, with nasal bleeding, crusting, and purulence. The nasal cavities may become enlarged, particularly in the primary form. (See <a class="local">'Nasal exam'</a> above and <a class="local">'Nasal exam findings'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The diagnosis of atrophic rhinosinusitis (either primary or secondary) is based upon the combination of suggestive symptoms, endoscopic findings, and radiographic results. Diagnostic criteria have been proposed. The possibility of an underlying and causative disease should be investigated in patients with apparent systemic illness. (See <a class="local">'Evaluation and diagnosis'</a> above and <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There are no controlled trials comparing therapies for atrophic rhinosinusitis. If secondary atrophic rhinosinusitis is due to an underlying active disease process, then therapy should focus on the underlying disease. (See <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We suggest nasal lavage with warmed normal <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> at least twice daily  (<a class="graphic graphic_table graphicRef78832" href="/z/d/graphic/78832.html" rel="external">table 2</a>) (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). After lavage, we suggest that patients lubricate the cleaned nasal mucosa with petroleum jelly, xylitol-containing saline sprays, or personal lubricants (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Nasal lavage and lubrication'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We suggest that an antibiotic be added to the lavage solution when the nasal wash or nasal discharge becomes purulent for more than two days  (<a class="graphic graphic_table graphicRef55661" href="/z/d/graphic/55661.html" rel="external">table 3</a>) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). This is continued until the purulence clears. (See <a class="local">'Antibiotics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Oral antibiotics are used for acute bacterial sinus infections. (See  <a class="medical medical_review" href="/z/d/html/83012.html" rel="external">"Uncomplicated acute sinusitis and rhinosinusitis in adults: Treatment", section on 'Antibiotics'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We suggest performing rhinoscopy at least twice yearly to remove synechiae and crusts as long as symptoms persist (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Monitoring'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We suggest against surgical procedures (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Other therapies'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Dutt SN, Kameswaran M. The aetiology and management of atrophic rhinitis. J Laryngol Otol 2005; 119:843.</a></li><li><a class="nounderline abstract_t">Zohar Y, Talmi YP, Strauss M, et al. Ozena revisited. J Otolaryngol 1990; 19:345.</a></li><li><a class="nounderline abstract_t">Bunnag C, Jareoncharsri P, Tansuriyawong P, et al. Characteristics of atrophic rhinitis in Thai patients at the Siriraj Hospital. Rhinology 1999; 37:125.</a></li><li><a class="nounderline abstract_t">Lee YJ, Moore LS, Almeyda J. A report on a rare case of Klebsiella ozaenae causing atrophic rhinitis in the UK. BMJ Case Rep 2011; 2011.</a></li><li><a class="nounderline abstract_t">Moore EJ, Kern EB. Atrophic rhinitis: a review of 242 cases. Am J Rhinol 2001; 15:355.</a></li><li><a class="nounderline abstract_t">Han-Sen C. The ozena problem. Clinical analysis of atrophic rhinitis in 100 cases. Acta Otolaryngol 1982; 93:461.</a></li><li><a class="nounderline abstract_t">Chand MS, MacArthur CJ. Primary atrophic rhinitis: a summary of four cases and review of the literature. Otolaryngol Head Neck Surg 1997; 116:554.</a></li><li><a class="nounderline abstract_t">El-Barbary A, Yassin A, Fouad H, Shennany M. Histopathological and histochemical study on atrophic rhinitis. J Laryngol Otolaryngol 1970; 84:1103.</a></li><li><a class="nounderline abstract_t">Kameswaran M. Fibre-optic endoscopy in atrophic rhinitis. J Laryngol Otol 1991; 105:1014.</a></li><li><a class="nounderline abstract_t">Sibert JR, Barton RP. Dominant inheritance in a family with primary atrophic rhinitis. J Med Genet 1980; 17:39.</a></li><li><a class="nounderline abstract_t">Abdel-Latif SM, Baheeg SS, Aglan YI, et al. Chronic atrophic rhinitis with fetor (ozena): a histopathologic tretise. Rhinology 1987; 25:117.</a></li><li><a class="nounderline abstract_t">Ferguson JL, McCaffrey TV, Kern EB, Martin WJ 2nd. Effect of Klebsiella ozaenae on ciliary activity in vitro: implications in the pathogenesis of atrophic rhinitis. Otolaryngol Head Neck Surg 1990; 102:207.</a></li><li><a class="nounderline abstract_t">Pace-Balzan A, Shankar L, Hawke M. Computed tomographic findings in atrophic rhinitis. J Otolaryngol 1991; 20:428.</a></li><li><a class="nounderline abstract_t">Castillo L, Verschuur HP, Poissonnet G, et al. Complications of endoscopically guided sinus surgery. Rhinology 1996; 34:215.</a></li><li><a class="nounderline abstract_t">Hildenbrand T, Weber RK, Brehmer D. Rhinitis sicca, dry nose and atrophic rhinitis: a review of the literature. Eur Arch Otorhinolaryngol 2011; 268:17.</a></li><li><a class="nounderline abstract_t">Ly TH, deShazo RD, Olivier J, et al. Diagnostic criteria for atrophic rhinosinusitis. Am J Med 2009; 122:747.</a></li><li><a class="nounderline abstract_t">deShazo RD, Stringer SP. Atrophic rhinosinusitis: progress toward explanation of an unsolved medical mystery. Curr Opin Allergy Clin Immunol 2011; 11:1.</a></li><li><a class="nounderline abstract_t">Mishra A, Kawatra R, Gola M. Interventions for atrophic rhinitis. Cochrane Database Syst Rev 2012; :CD008280.</a></li><li><a class="nounderline abstract_t">Tomooka LT, Murphy C, Davidson TM. Clinical study and literature review of nasal irrigation. Laryngoscope 2000; 110:1189.</a></li><li><a class="nounderline abstract_t">Leonard DW, Bolger WE. Topical antibiotic therapy for recalcitrant sinusitis. Laryngoscope 1999; 109:668.</a></li><li><a class="nounderline abstract_t">Sinha SN, Sardana DS, Rajvanshi VS. A nine years' review of 273 cases of atrophic rhinitis and its management. J Laryngol Otol 1977; 91:591.</a></li><li><a class="nounderline abstract_t">Jaswal A, Jana AK, Sikder B, et al. Novel treatment of atrophic rhinitis: early results. Eur Arch Otorhinolaryngol 2008; 265:1211.</a></li><li><a class="nounderline abstract_t">Leong SC. The clinical efficacy of surgical interventions for empty nose syndrome: A systematic review. Laryngoscope 2015; 125:1557.</a></li></ol></div><div id="topicVersionRevision">Topic 7531 Version 20.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16354334" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The aetiology and management of atrophic rhinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2262956" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Ozena revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10567992" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Characteristics of atrophic rhinitis in Thai patients at the Siriraj Hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22669526" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : A report on a rare case of Klebsiella ozaenae causing atrophic rhinitis in the UK.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11777241" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Atrophic rhinitis: a review of 242 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7102303" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The ozena problem. Clinical analysis of atrophic rhinitis in 100 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9141411" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Primary atrophic rhinitis: a summary of four cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Histopathological and histochemical study on atrophic rhinitis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1787352" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Fibre-optic endoscopy in atrophic rhinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7365761" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Dominant inheritance in a family with primary atrophic rhinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3616392" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Chronic atrophic rhinitis with fetor (ozena): a histopathologic tretise.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2108406" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Effect of Klebsiella ozaenae on ciliary activity in vitro: implications in the pathogenesis of atrophic rhinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1774803" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Computed tomographic findings in atrophic rhinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9050099" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Complications of endoscopically guided sinus surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20878413" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Rhinitis sicca, dry nose and atrophic rhinitis: a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19540453" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Diagnostic criteria for atrophic rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21157302" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Atrophic rhinosinusitis: progress toward explanation of an unsolved medical mystery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22336840" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Interventions for atrophic rhinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10892694" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Clinical study and literature review of nasal irrigation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10201762" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Topical antibiotic therapy for recalcitrant sinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19546" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A nine years' review of 273 cases of atrophic rhinitis and its management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18317788" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Novel treatment of atrophic rhinitis: early results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25647010" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The clinical efficacy of surgical interventions for empty nose syndrome: A systematic review.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
